GSK rep wears dunce cap for off-label breach

It's the sort of code-of-practice violation that doesn't typically make headlines outside of the trade press. But this time, it's the context that counts. Just months after CEO Andrew Witty vowed to stamp out marketing missteps, GlaxoSmithKline ($GSK) was slapped on the hand by the U.K.'s self-governing pharma board, for a sales rep's off-label promotion. The sales rep apparently emailed a National Health Sevice consultant about using the company's Revolade drug to treat myeloid fibrosis, an off-label use. According to the Prescription Medicines Code of Practice Authority, the rep's activities breached the industry's code. Report


Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.